Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BMN 349

Gene therapy · developed by BioMarin Pharmaceutical

Phase 1 Most advanced trial
BMRN Developer
1 Registered trials

What is BMN 349?

BMN 349 is a gene therapy investigated in alpha-1 antitrypsin deficiency, a condition caused by defective SERPINA1 gene function. The approach is designed to deliver a gene that supports alpha-1 antitrypsin production in the body.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Therapy area
Respiratory
Developer
BioMarin Pharmaceutical (BMRN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06738017 Phase 1 Alpha 1-Antitrypsin Deficiency Active not recruiting BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alpha 1-Antitrypsin Deficiency

More from BioMarin Pharmaceutical

Follow BMRN, the company behind BMN 349

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.